A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination With Palliative Radiotherapy in Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2018
At a glance
- Drugs M 3541 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors EMD Serono Research & Development Institute
- 12 Mar 2018 Planned End Date changed from 25 Sep 2019 to 31 Dec 2019.
- 12 Mar 2018 Planned primary completion date changed from 25 Mar 2019 to 3 Jul 2019.
- 09 Jan 2018 Planned number of patients changed from 30 to 24.